About
Intima Bioscience is a clinical-stage biotechnology company developing next-generation small molecule checkpoint inhibitors targeting the intracellular immune checkpoint CISH, employing CRISPR-engineered T-cell therapies in cancer treatment clinical trials.
Explore Intima Bioscience's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.